152 related articles for article (PubMed ID: 35193583)
1. Carrier-free multifunctional nanomedicine for intraperitoneal disseminated ovarian cancer therapy.
Huang X; Qiu M; Wang T; Li B; Zhang S; Zhang T; Liu P; Wang Q; Qian ZR; Zhu C; Wu M; Zhao J
J Nanobiotechnology; 2022 Feb; 20(1):93. PubMed ID: 35193583
[TBL] [Abstract][Full Text] [Related]
2. Engineering Chemotherapeutic-Augmented Calcium Phosphate Nanoparticles for Treatment of Intraperitoneal Disseminated Ovarian Cancer.
Qiu M; Chen J; Huang X; Li B; Zhang S; Liu P; Wang Q; Qian ZR; Pan Y; Chen Y; Zhao J
ACS Appl Mater Interfaces; 2022 May; 14(19):21954-21965. PubMed ID: 35508299
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
Iizuka K; Jin C; Eshima K; Hong MH; Eshima K; Fukushima M
Drug Des Devel Ther; 2018; 12():673-683. PubMed ID: 29636601
[TBL] [Abstract][Full Text] [Related]
4. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
5. A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.
Ando H; Fukushima M; Eshima K; Hasui T; Shimizu T; Ishima Y; Huang CL; Wada H; Ishida T
Cancer Med; 2019 Dec; 8(17):7313-7321. PubMed ID: 31609087
[TBL] [Abstract][Full Text] [Related]
6. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.
Hashimoto K; Morishige K; Sawada K; Tahara M; Kawagishi R; Ikebuchi Y; Sakata M; Tasaka K; Murata Y
Cancer Res; 2005 Jan; 65(2):540-5. PubMed ID: 15695397
[TBL] [Abstract][Full Text] [Related]
7. Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
Yang Z; Liu Y; Wei X; Zhou X; Gong C; Zhang T; Jin P; Xu S; Ma D; Gao Q
Curr Cancer Drug Targets; 2015; 15(3):215-26. PubMed ID: 25619386
[TBL] [Abstract][Full Text] [Related]
8. Engineering Alendronate-Composed Iron Nanochelator for Efficient Peritoneal Carcinomatosis Treatment.
Zhao J; Huang X; Liu P; Qiu M; Li B; Wen Y; Li Y; Wang Q; Wu M; Chen Y; Pan Y
Adv Sci (Weinh); 2022 Oct; 9(30):e2203031. PubMed ID: 36057999
[TBL] [Abstract][Full Text] [Related]
9. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
[TBL] [Abstract][Full Text] [Related]
10. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
[No Abstract] [Full Text] [Related]
11. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
Hijaz M; Das S; Mert I; Gupta A; Al-Wahab Z; Tebbe C; Dar S; Chhina J; Giri S; Munkarah A; Seal S; Rattan R
BMC Cancer; 2016 Mar; 16():220. PubMed ID: 26979107
[TBL] [Abstract][Full Text] [Related]
12. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
13. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
14. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer.
Wang J; Li Z; Mei H; Zhang D; Wu G; Zhang T; Lin Z
Anticancer Drugs; 2019 Jun; 30(5):466-474. PubMed ID: 30694816
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.
Bolyard C; Yoo JY; Wang PY; Saini U; Rath KS; Cripe TP; Zhang J; Selvendiran K; Kaur B
Clin Cancer Res; 2014 Dec; 20(24):6479-94. PubMed ID: 25294909
[TBL] [Abstract][Full Text] [Related]
18. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
Liu B; Huang X; Li Y; Liao W; Li M; Liu Y; He R; Feng D; Zhu R; Kurihara H
BMC Cancer; 2019 Jul; 19(1):645. PubMed ID: 31262254
[TBL] [Abstract][Full Text] [Related]
19. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1.
Ying L; Chunxia Y; Wei L
Cancer Chemother Pharmacol; 2015 Sep; 76(3):641-50. PubMed ID: 26228528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
